Use of gemtuzumab ozogamicin in relapsed refractory acute myeloid leukemia: Multi-center real life data from Turkey. (2021)

• Record Type: Journal Article
• Authors: Küçükdiler, Ayşe Hilal Eroğlu; Yavaşoğlu, İrfan; Selim, Cem; Mutlu, Cansu Atmaca; Karakuş, Abdullah; Koyuncu, Mahmut Bakır; Bilgir, Oktay; Ayyıldız, Orhan; Tiftik, Eyüp Naci; Bolaman, Ali Zahit
• Is Part Of: Leukemia research reports. Volume 16(2021)
• Publication Date: 2021
• Subjects: Gemtuzumab ozogamicin -- Acute myeloid leukemia -- Salvage treatment; Leukemia -- Periodicals; Lymphomas -- Periodicals; Multiple myeloma -- Periodicals; Leukemia -- Periodicals; Lymphoma -- Periodicals; Multiple Myeloma -- Periodicals; Hematologic Neoplasms -- Periodicals; Leukemia; Lymphomas; Multiple myeloma; Electronic journals; Periodicals; 616.9941905
• DOI: 10.1016/j.lrr.2021.100280
• Languages: English
• ISSNs: 2213-0489

Abstract

Abstract: We retrospectively evaluated the use of gemtuzumab ozogamicin (GO) in relapsed refractory (R/R) acute myeloid leukemia (AML) patients. Twenty-one CD33 positive R/R AML patients who received GO as a single agent in 4 hematology centers were included in this study. The median age was 59, and the median ECOG performance score was 2. According to cytogenetic analysis, 1 patient had favorable risk, 12 patients with intermediate, and 8 patients with adverse risk. The overall response rate was 52.3%. Partial response was achieved in 3 of 8 patients with adverse risk. 33.3% of patients developed grade 3 anemia. Grade 4 neutropenia and thrombocytopenia were observed in 80% of the patients. One of the patients died due to sinusoidal obstruction syndrome / veno-occlusive disease (SOS / VOD) due to GO side effects. GO may be considered as a good option for salvage therapy in R/R AML patients.